€7 million raised – market capitalisation of approx. €31 million
Brussels and Paris – 17 June 2021 – Euronext today congratulates TheraVet, a vet biotech company developing new treatments specifically adapted to pets, on its dual listing on Euronext Growth® Paris and Euronext Growth® Brussels (ticker code: ALVET).
Headquartered in Belgium (Jumet, Wallonia) with an US-based subsidiary, TheraVet's mission is to develop innovative, safe and effective treatments to improve the well-being and quality of life of companion animals suffering from osteoarticular diseases. TheraVet's main targets (indications & applications) are bone surgery with BIOCERA-VET product line in cats and dogs as well as horses and osteoarthritis & ligament & tendon injuries with VISCO-VET product line in dogs.
TheraVet was listed through the admission to trading of the 3,223,936 shares making up its equity, including 734,636 new shares issued under a Public Offering.
The admission and issue price of TheraVet shares was set at €9.60 per share. Market capitalisation was €30.9 million on the day of listing. The offering raised €7.05 million altogether.
Enrico Bastianelli, Founder and CEO of TheraVet, said: “We are proud of the success achieved by TheraVet’s IPO on Euronext Growth Paris et Brussels, and we offer our sincere thanks to all of our new retail and institutional shareholders. We specialise in osteoarticular treatments and we now have the financial resources we need to carry out clinical development in our two product ranges and to market them in Europe and the United States.”
Caption: Enrico Bastianelli, Founder and CEO of TheraVet, and his team rang the bell during a ceremony this morning together with Vincent Van Dessel, CEO of Euronext Brussels, to celebrate the Initial Public Offering of the company.
About TheraVet TheraVet is a veterinary biotechnology company specializing in osteoarticular treatments for animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from osteoarticular diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris et Brussels, its head office is in Jumet, Belgium, and it has a subsidiary in the US. For more information, visit www.thera.vet